You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTerbinafine
Accession NumberDB00857  (APRD00508)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionTerbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal. It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (squalene 2,3-epoxidase), an enzyme that is part of the fungal cell wall synthesis pathway.
Structure
Thumb
Synonyms
(e)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine
(e)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine
Terbinafina
Terbinafinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act TerbinafineTablet250 mgOralActavis Pharma Company2005-02-11Not applicableCanada
Auro-terbinafineTablet250 mgOralAuro Pharma Inc2011-05-30Not applicableCanada
Auro-terbinafineTablet125 mgOralAuro Pharma IncNot applicableNot applicableCanada
Dom-terbinafineTablet250 mgOralDominion Pharmacal2011-03-03Not applicableCanada
Jamp-terbinafineTablet250 mgOralJamp Pharma Corporation2010-10-24Not applicableCanada
LamisilGranule125 mg/1OralNovartis Pharmaceuticals Corporation2007-09-28Not applicableUs
LamisilGranule187.5 mg/1OralNovartis Pharmaceuticals Corporation2007-09-28Not applicableUs
LamisilTablet250 mg/1OralNovartis Pharmaceuticals Corporation1996-05-10Not applicableUs
Lamisil Crm 1%Cream1 %TopicalNovartis Pharmaceuticals Canada Inc1993-12-31Not applicableCanada
Lamisil DermgelGel10 mgTopicalNovartis Pharmaceuticals Canada IncNot applicableNot applicableCanada
Lamisil SpraySpray10 mgTopicalNovartis Pharmaceuticals Canada Inc1999-01-05Not applicableCanada
Lamisil Tab 250mgTablet250 mgOralNovartis Pharmaceuticals Canada Inc1993-12-31Not applicableCanada
Mylan-terbinafineTablet250 mgOralMylan Pharmaceuticals Ulc2000-11-20Not applicableCanada
Nu-terbinafineTablet250 mgOralNu Pharm Inc2004-07-242012-09-04Canada
PHL-terbinafineTablet250 mgOralPharmel Inc2007-10-202016-10-25Canada
PMS-terbinafineTablet250 mgOralPharmascience Inc2000-02-14Not applicableCanada
PMS-terbinafineTablet250 mgOralPharmascience Inc2009-06-19Not applicableCanada
PMS-terbinafine CreamCream1 %TopicalPharmascience IncNot applicableNot applicableCanada
PMS-terbinafine SpraySpray1 %TopicalPharmascience IncNot applicableNot applicableCanada
Q-terbinafineTablet250 mgOralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Riva-terbinafineTablet250 mgOralLaboratoire Riva Inc2005-02-10Not applicableCanada
Sandoz-terbinafineTablet250 mgOralSandoz Canada Incorporated2005-12-07Not applicableCanada
TerbinafineTablet250 mgOralSanis Health Inc2010-07-26Not applicableCanada
TerbinafineTablet250 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
TerbinafineTablet250 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
TerbinafineTablet250 mgOralPro Doc Limitee2008-03-07Not applicableCanada
TerbinafineTablet250 mgOralPrempharm Inc2003-09-032005-08-05Canada
Teva-terbinafineTablet125 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Teva-terbinafineTablet250 mgOralTeva Canada Limited2001-02-28Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-terbinafineTablet250 mgOralApotex Inc2000-05-16Not applicableCanada
TerbinafineTablet250 mg/1OralExelan Pharmaceuticals Inc.2012-04-25Not applicableUs
TerbinafineTablet250 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-07-02Not applicableUs
TerbinafineTablet250 1/1OralCipla USA Inc.2016-06-27Not applicableUs
TerbinafineTablet250 mg/1OralPd Rx Pharmaceuticals, Inc.2007-07-30Not applicableUs
TerbinafineTablet250 mg/1OralHarris Pharmaceutical, Inc.2007-07-30Not applicableUs
TerbinafineTablet250 mg/1OralAurobindo Pharma Limited2007-07-02Not applicableUs
Terbinafine HydochlorideTablet250 mg/1OralPhysicians Total Care, Inc.2007-07-12Not applicableUs
Terbinafine HydrochlorideTablet250 mg/1OralWockhardt USA, LLC2008-01-04Not applicableUs
Terbinafine HydrochlorideTablet250 mg/1OralRebel Distributors Corp2007-07-02Not applicableUs
Terbinafine HydrochlorideCream1 g/100gTopicalREMEDYREPACK INC.2015-03-12Not applicableUs
Terbinafine HydrochlorideTablet250 1/1OralA S Medication Solutions2011-01-01Not applicableUs
Terbinafine HydrochlorideTablet250 mg/1OralPd Rx Pharmaceuticals, Inc.2014-08-13Not applicableUs
Terbinafine HydrochlorideTablet250 mg/1OralAmerican Health Packaging2014-07-31Not applicableUs
Terbinafine HydrochlorideTablet250 mg/1OralDr.Reddys Laboratories Limited2007-07-02Not applicableUs
Terbinafine HydrochlorideTablet250 mg/1OralWockhardt USA LLC.2007-07-02Not applicableUs
Terbinafine HydrochlorideTablet250 1/1OralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs
Terbinafine HydrochlorideTablet250 mg/1OralDIRECT RX2015-01-01Not applicableUs
Terbinafine HydrochlorideTablet250 mg/1OralA S Medication Solutions2010-12-27Not applicableUs
Terbinafine HydrochlorideTablet250 mg/1OralBreckenridge Pharmaceutical, Inc.2010-12-27Not applicableUs
Terbinafine HydrochlorideTablet250 1/1OralCarilion Materials Management2011-01-01Not applicableUs
Terbinafine HydrochlorideTablet250 mg/1OralWockhardt Limited2007-07-02Not applicableUs
Terbinafine HydrochlorideTablet250 mg/1OralNorthstar Rx LLC2009-09-15Not applicableUs
Terbinafine HydrochlorideTablet250 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-09-16Not applicableUs
Terbinafine HydrochlorideTablet250 mg/1OralHarris Pharmaceutical, Inc.2014-08-13Not applicableUs
Terbinafine HydrochlorideTablet250 1/1OralProficient Rx LP2011-01-01Not applicableUs
Terbinafine HydrochlorideTablet250 mg/1OralPreferred Pharmaceuticals, Inc2011-06-29Not applicableUs
Terbinafine HydrochlorideTablet250 mg/1OralREMEDYREPACK INC.2013-02-112016-04-05Us
Terbinafine HydrochlorideTablet250 mg/1OralGolden State Medical Supply, Inc.2010-12-27Not applicableUs
Terbinafine HydrochlorideTablet250 mg/1OralAv Kare, Inc.2011-10-20Not applicableUs
Terbinafine HydrochlorideTablet250 mg/1Oralbryant ranch prepack2011-01-01Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AntifungalCream1 g/100gTopicalMeijer Distribution Inc2007-07-02Not applicableUs
Antifungal FootCream1 g/100gTopicalAmerican Sales Company2007-07-02Not applicableUs
Athletes FootCream1 g/100gTopicalChain Drug Marketing Association, Inc.2007-07-02Not applicableUs
Athletes FootCream10 mg/gTopicalNovartis Cosnumer Health, Inc2009-08-31Not applicableUs
Athletes FootCream1 g/100gTopicalTarget Corporation2007-07-02Not applicableUs
Athletes FootCream1 g/100gTopicalH E B2007-07-02Not applicableUs
Athletes FootCream1 g/100gTopicalTopco Associates LLC2007-07-02Not applicableUs
Athletes FootCream10 mg/gTopicalTarget Corporation2009-08-31Not applicableUs
Athletes FootCream1 g/100gTopicalSupervalu Inc2007-07-02Not applicableUs
Athletes FootCream1 g/100gTopicalPublix Super Markets Inc.2007-07-02Not applicableUs
Athletes FootCream1 g/100gTopicalSafeway Inc.2007-07-02Not applicableUs
Athletes FootCream1 g/100gTopicalMc Kesson2007-07-02Not applicableUs
CvsCream1 g/100gTopicalCVS Pharmacy2007-07-02Not applicableUs
Cvs Pharmacy Athletes FootCream1 g/100gTopicalCVS Pharmacy2007-07-02Not applicableUs
Equate Athletes FootCream1 g/100gTopicalWal Mart Stores Inc2007-07-02Not applicableUs
Good Neighbor PharmacyCream1 g/100gTopicalAmerisource Bergen2007-07-02Not applicableUs
Goodsense Terbinafine HydrochlorideCream1 g/100gTopicalGeiss, Destin & Dunn, Inc.2007-07-02Not applicableUs
Kaiser Permanente Terbinafine HydrochlorideCream1 g/100gTopicalKAISER FOUNDATION HOSPITALS2007-07-02Not applicableUs
Kroger AntifungalCream1 g/100gTopicalKroger Company2007-07-02Not applicableUs
LamisilSpray1.25 mL/125mLTopicalPhysicians Total Care, Inc.2010-04-13Not applicableUs
Lamisil AtCream10 mg/gTopicalNovartis Consumer Health, Inc.2005-08-10Not applicableUs
Lamisil AtSpray1 mL/100mLTopicalNovartis Consumer Health, Inc.2000-05-01Not applicableUs
Lamisil AtCream1 g/100gTopicalGlaxo Smith Kline Consumer Healthcare Holdings (Us) Llc2007-07-02Not applicableUs
Lamisil AtCream10 mg/gTopicalNovartis Consumer Health, Inc.2005-08-10Not applicableUs
Lamisil At AntifungalGel10 mg/gTopicalNovartis Consumer Health, Inc.2010-01-01Not applicableUs
Lamisil At Continuous SprayLiquid1.25 mL/125mLTopicalNovartis Consumer Health, Inc.2009-07-23Not applicableUs
Lamisil At Continuous SprayLiquid1.25 mL/125mLTopicalNovartis Consumer Health, Inc.2009-07-23Not applicableUs
Lamisil At for Jock ItchCream1 g/100gTopicalNovartis Consumer Health, Inc.2007-07-02Not applicableUs
Lamisil At Jock ItchCream10 mg/gTopicalNovartis Consumer Health, Inc.2006-12-08Not applicableUs
Live Better AntifungalCream1 g/100gTopicalThe Great Atlantic & Pacific Tea Company2007-07-02Not applicableUs
Preferred PlusCream1 g/100gTopicalPreferred Plus (Kinray)2007-07-02Not applicableUs
Shopko Athletes FootCream1 g/100gTopicalShopko Stores Operating Co., LLC2007-07-02Not applicableUs
ShopriteCream1 g/100gTopicalWakefern Food Corporation2007-07-02Not applicableUs
Silka AntifungalCream1 g/100gTopicalGenomma Lab Usa, Inc.2007-07-02Not applicableUs
Terbinafine HydrochlorideCream1 g/100gTopicalPhysicians Total Care, Inc.2009-02-24Not applicableUs
Terbinafine HydrochlorideCream1 g/100gTopicalChain Drug Constortium2007-07-02Not applicableUs
Terbinafine HydrochlorideCream1 g/100gTopicalPreferred Pharmaceuticals, Inc2012-04-05Not applicableUs
Terbinafine HydrochlorideCream1 g/100gTopicalProficient Rx LP2007-07-02Not applicableUs
Terbinafine HydrochlorideCream1 g/100gTopicalWalgreen Company2007-07-02Not applicableUs
Terbinafine HydrochlorideCream1 g/100gTopicalCardinal Health2007-07-02Not applicableUs
Terbinafine HydrochlorideCream1 g/100gTopicalTaro Pharmaceuticals U.S.A., Inc.2007-07-02Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
LamasilNot Available
TerbinexNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Terbinafine Hydrochloride
78628-80-5
Thumb
  • InChI Key: BWMISRWJRUSYEX-SZKNIZGXSA-N
  • Monoisotopic Mass: 327.175377544
  • Average Mass: 327.891
DBSALT000470
Categories
UNIIG7RIW8S0XP
CAS number91161-71-6
WeightAverage: 291.4299
Monoisotopic: 291.198699805
Chemical FormulaC21H25N
InChI KeyDOMXUEMWDBAQBQ-WEVVVXLNSA-N
InChI
InChI=1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+
IUPAC Name
[(2E)-6,6-dimethylhept-2-en-4-yn-1-yl](methyl)(naphthalen-1-ylmethyl)amine
SMILES
CN(C\C=C\C#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12
Pharmacology
IndicationFor the treatment of dermatophyte infections of the toenail or fingernail caused by susceptible fungi. Also for the treatment of tinea capitis (scalp ringworm) and tinea corporis (body ringworm) or tinea cruris (jock itch).
Structured Indications
PharmacodynamicsTerbinafine is an allylamine antifungal agent and acts by inhibiting squalene epoxidase, thus blocking the biosynthesis of ergosterol, an essential component of fungal cell membranes. In vitro, mammalian squalene monooxygenase (squalene 2,3-epoxidase) is only inhibited at higher (4000 fold) concentrations than is needed for inhibition of the dermatophyte enzyme. Depending on the concentration of the drug and the fungal species test in vitro, Terbinafine may be fungicidal. However, the clinical significance of in vitro data is unknown.
Mechanism of actionTerbinafine is hypothesized to act by inhibiting squalene monooxygenase, thus blocking the biosynthesis of ergosterol, an essential component of fungal cell membranes. This inhibition also results in an accumulation of squalene, which is a substrate catalyzed to 2,3-oxydo squalene by squalene monooxygenase. The resultant high concentration of squalene and decreased amount of ergosterol are both thought to contribute to terbinafine's antifungal activity.
TargetKindPharmacological actionActionsOrganismUniProt ID
Squalene monooxygenaseProteinyes
inhibitor
HumanQ14534 details
Related Articles
AbsorptionReadily absorbed from gastrointestinal tract.
Volume of distributionNot Available
Protein binding>99%
Metabolism

Hepatic

SubstrateEnzymesProduct
Terbinafine
HydroxyterbinafineDetails
Terbinafine
N-DesmethylterbinafineDetails
Terbinafine
1-NaphtaldehydeDetails
Hydroxyterbinafine
Not Available
CarboxyterbinafineDetails
Hydroxyterbinafine
Not Available
N-DesmethylhydroxyterbinafineDetails
N-Desmethylterbinafine
Not Available
N-DesmethylhydroxyterbinafineDetails
1-Naphtaldehyde
1-Naphthoic acidDetails
1-Naphtaldehyde
1-NahthalenethanolDetails
Terbinafine
Terbinafine dihydrodiol derivative (1)Details
Terbinafine
Terbinafine dihydrodiol derivative (2)Details
N-Desmethylterbinafine
Not Available
N-Desmethylterbinafine dihydrodiol derivative (1)Details
N-Desmethylterbinafine
Not Available
N-Desmethylterbinafine dihydrodiol derivative (2)Details
Terbinafine
Not Available
N-Desmethylterbinafine dihydrodiol derivative (1)Details
Terbinafine
Not Available
N-Desmethylterbinafine dihydrodiol derivative (2)Details
Route of eliminationPrior to excretion, terbinafine is extensively metabolized.
Half life36 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Fungi
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Terbinafine.Experimental, Illicit
AbirateroneThe serum concentration of Terbinafine can be increased when it is combined with Abiraterone.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Terbinafine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Terbinafine.Approved
AjmalineThe metabolism of Ajmaline can be decreased when combined with Terbinafine.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Terbinafine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Terbinafine.Approved
AlprenololThe metabolism of Alprenolol can be decreased when combined with Terbinafine.Approved, Withdrawn
AmineptineThe metabolism of Amineptine can be decreased when combined with Terbinafine.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Terbinafine.Approved, Withdrawn
AmiodaroneThe metabolism of Terbinafine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Terbinafine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Amlodipine.Approved
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Terbinafine.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Terbinafine.Approved, Illicit
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Terbinafine.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Terbinafine.Approved
AmrinoneThe risk or severity of adverse effects can be increased when Terbinafine is combined with Amrinone.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Terbinafine.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Terbinafine.Approved
AprepitantThe serum concentration of Terbinafine can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Terbinafine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Terbinafine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Terbinafine.Approved, Investigational
ArmodafinilThe metabolism of Terbinafine can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Terbinafine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Terbinafine.Approved, Withdrawn
AtazanavirThe metabolism of Terbinafine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Terbinafine.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Terbinafine.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Azelnidipine.Approved
AzimilideThe risk or severity of adverse effects can be increased when Terbinafine is combined with Azimilide.Investigational
AzithromycinThe metabolism of Terbinafine can be decreased when combined with Azithromycin.Approved
BarnidipineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Barnidipine.Approved
BenidipineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Benidipine.Approved
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Terbinafine.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Terbinafine.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Terbinafine.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Terbinafine.Approved
BexaroteneThe serum concentration of Terbinafine can be decreased when it is combined with Bexarotene.Approved, Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Terbinafine.Approved
BoceprevirThe metabolism of Terbinafine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Bortezomib can be decreased when combined with Terbinafine.Approved, Investigational
BosentanThe serum concentration of Terbinafine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Terbinafine.Approved
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Terbinafine.Approved
BufuralolThe metabolism of Bufuralol can be decreased when combined with Terbinafine.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Terbinafine.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Terbinafine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Terbinafine.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Terbinafine.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Terbinafine.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Terbinafine.Approved
CaiThe risk or severity of adverse effects can be increased when Terbinafine is combined with Cai.Investigational
CapecitabineThe metabolism of Terbinafine can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Terbinafine.Approved
CarbamazepineThe metabolism of Terbinafine can be increased when combined with Carbamazepine.Approved, Investigational
CariprazineThe metabolism of Cariprazine can be decreased when combined with Terbinafine.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Terbinafine.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Terbinafine.Approved, Investigational
CelecoxibThe metabolism of Terbinafine can be decreased when combined with Celecoxib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Terbinafine.Approved, Vet Approved
CeritinibThe serum concentration of Terbinafine can be increased when it is combined with Ceritinib.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Terbinafine.Approved
ChloramphenicolThe metabolism of Terbinafine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Terbinafine.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Terbinafine.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Terbinafine.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Terbinafine.Approved, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Terbinafine.Approved
CholecalciferolThe metabolism of Terbinafine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilnidipineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Cilnidipine.Approved
CilostazolThe metabolism of Cilostazol can be decreased when combined with Terbinafine.Approved
CimetidineThe metabolism of Terbinafine can be decreased when combined with Cimetidine.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Terbinafine.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Terbinafine.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Citalopram can be decreased when combined with Terbinafine.Approved
ClarithromycinThe metabolism of Terbinafine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Terbinafine can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Terbinafine.Approved
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Terbinafine.Approved, Vet Approved
ClonidineThe metabolism of Clonidine can be decreased when combined with Terbinafine.Approved
ClopidogrelThe metabolism of Terbinafine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Terbinafine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Terbinafine.Approved
CobicistatThe metabolism of Terbinafine can be decreased when combined with Cobicistat.Approved
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Terbinafine.Approved, Illicit
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Terbinafine.Approved, Investigational
CrizotinibThe metabolism of Terbinafine can be decreased when combined with Crizotinib.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Terbinafine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Terbinafine.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Terbinafine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Terbinafine can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Terbinafine.Approved
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Terbinafine.Approved, Investigational
DarodipineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Darodipine.Experimental
DarunavirThe metabolism of Terbinafine can be decreased when combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Terbinafine.Approved
DasatinibThe serum concentration of Terbinafine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Terbinafine.Approved
DeferasiroxThe serum concentration of Terbinafine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Terbinafine can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Terbinafine.Approved
DexamethasoneThe serum concentration of Terbinafine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Terbinafine.Approved, Illicit, Withdrawn
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Terbinafine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Terbinafine.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Terbinafine.Approved
DidanosineDidanosine can cause a decrease in the absorption of Terbinafine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Terbinafine.Approved, Illicit
DihydroergotamineThe metabolism of Terbinafine can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Terbinafine.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Terbinafine.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Terbinafine.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Terbinafine.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Terbinafine.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Terbinafine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Terbinafine.Approved
DosulepinThe metabolism of Dosulepin can be decreased when combined with Terbinafine.Approved
DotarizineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Dotarizine.Investigational
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Terbinafine.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Terbinafine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Terbinafine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Terbinafine.Approved, Investigational
DoxycyclineThe metabolism of Terbinafine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Terbinafine.Approved
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Terbinafine.Approved
EfavirenzThe serum concentration of Terbinafine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Terbinafine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Terbinafine.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Terbinafine.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Terbinafine.Investigational
EnzalutamideThe serum concentration of Terbinafine can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Terbinafine is combined with Eperisone.Approved, Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Terbinafine.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Terbinafine.Approved, Investigational
ErythromycinThe metabolism of Terbinafine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Terbinafine.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Terbinafine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Terbinafine.Investigational
EsomeprazoleThe metabolism of Terbinafine can be decreased when combined with Esomeprazole.Approved, Investigational
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Terbinafine.Approved, Illicit
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Terbinafine.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Terbinafine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Fendiline.Withdrawn
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Terbinafine.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Terbinafine.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Terbinafine.Approved, Withdrawn
FloxuridineThe metabolism of Terbinafine can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Terbinafine can be decreased when combined with Fluconazole.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Terbinafine.Approved
FluorouracilThe metabolism of Terbinafine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Terbinafine.Approved, Vet Approved
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Terbinafine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Terbinafine.Approved
FluvoxamineThe metabolism of Terbinafine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Terbinafine.Approved, Investigational
FosamprenavirThe metabolism of Terbinafine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Terbinafine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Terbinafine can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Terbinafine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Terbinafine is combined with Gabapentin.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Terbinafine.Approved
GallopamilThe risk or severity of adverse effects can be increased when Terbinafine is combined with Gallopamil.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Terbinafine.Approved, Investigational
GemfibrozilThe metabolism of Terbinafine can be decreased when combined with Gemfibrozil.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Terbinafine.Approved, Investigational
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Terbinafine.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Terbinafine.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Terbinafine.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Terbinafine.Approved, Illicit
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Terbinafine.Approved, Illicit
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Terbinafine.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Terbinafine.Approved
IdelalisibThe serum concentration of Terbinafine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Terbinafine.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Terbinafine.Approved
ImipramineThe metabolism of Imipramine can be decreased when combined with Terbinafine.Approved
IndinavirThe metabolism of Terbinafine can be decreased when combined with Indinavir.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Terbinafine.Approved
IrbesartanThe metabolism of Terbinafine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Terbinafine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Terbinafine can be decreased when combined with Isoniazid.Approved
IsradipineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Isradipine.Approved
ItraconazoleThe metabolism of Terbinafine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Terbinafine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Terbinafine.Approved
KetoconazoleThe metabolism of Terbinafine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Terbinafine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Lacidipine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Lamotrigine.Approved, Investigational
LapatinibThe metabolism of Terbinafine can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Terbinafine can be decreased when combined with Leflunomide.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Lercanidipine.Approved, Investigational
LevodopaThe metabolism of Levodopa can be decreased when combined with Terbinafine.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Terbinafine.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Terbinafine.Approved, Vet Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Terbinafine.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Terbinafine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Terbinafine.Approved
LopinavirThe metabolism of Terbinafine can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Terbinafine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Terbinafine.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Terbinafine.Approved
LovastatinThe metabolism of Terbinafine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Terbinafine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Terbinafine can be increased when it is combined with Lumacaftor.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Terbinafine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Manidipine.Approved
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Terbinafine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Terbinafine.Investigational, Withdrawn
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Terbinafine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Terbinafine.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Terbinafine.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Terbinafine.Approved, Illicit
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Terbinafine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Terbinafine.Approved, Vet Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Terbinafine.Approved, Investigational
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Terbinafine.Approved, Illicit, Withdrawn
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Terbinafine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Terbinafine.Approved, Investigational
MexiletineThe metabolism of Terbinafine can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Terbinafine.Approved
MibefradilThe risk or severity of adverse effects can be increased when Terbinafine is combined with Mibefradil.Withdrawn
MifepristoneThe serum concentration of Terbinafine can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Terbinafine.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Terbinafine.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Terbinafine.Approved
MitotaneThe serum concentration of Terbinafine can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Terbinafine.Approved
ModafinilThe serum concentration of Terbinafine can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe metabolism of Morphine can be decreased when combined with Terbinafine.Approved, Investigational
NafcillinThe serum concentration of Terbinafine can be decreased when it is combined with Nafcillin.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Terbinafine is combined with Naftopidil.Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Terbinafine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Terbinafine.Approved, Investigational
NefazodoneThe metabolism of Terbinafine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Terbinafine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Terbinafine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Terbinafine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Terbinafine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Terbinafine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Terbinafine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Terbinafine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Niguldipine.Experimental
NilotinibThe metabolism of Terbinafine can be decreased when combined with Nilotinib.Approved, Investigational
NiludipineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Terbinafine is combined with Nimesulide.Approved, Withdrawn
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Terbinafine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Nitrendipine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Terbinafine.Approved, Vet Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Terbinafine.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Terbinafine.Approved, Investigational
OlaparibThe metabolism of Terbinafine can be decreased when combined with Olaparib.Approved
OmeprazoleThe metabolism of Terbinafine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Terbinafine.Approved
OpipramolThe metabolism of Opipramol can be decreased when combined with Terbinafine.Investigational
OsimertinibThe serum concentration of Terbinafine can be increased when it is combined with Osimertinib.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Terbinafine.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Terbinafine can be increased when it is combined with Palbociclib.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Terbinafine.Approved, Investigational
PantoprazoleThe metabolism of Terbinafine can be decreased when combined with Pantoprazole.Approved
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Terbinafine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Terbinafine.Approved
Peginterferon alfa-2bThe serum concentration of Terbinafine can be increased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Terbinafine.Approved
PentobarbitalThe metabolism of Terbinafine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Terbinafine.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Terbinafine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Terbinafine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Terbinafine.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Terbinafine.Approved, Withdrawn
PhenobarbitalThe metabolism of Terbinafine can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Terbinafine.Approved, Vet Approved
PimozideTerbinafine may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Terbinafine is combined with Pinaverium.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Terbinafine.Approved
PioglitazoneThe metabolism of Terbinafine can be decreased when combined with Pioglitazone.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Terbinafine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Terbinafine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Terbinafine.Approved
PosaconazoleThe metabolism of Terbinafine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Terbinafine is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Prenylamine.Withdrawn
PrimidoneThe metabolism of Terbinafine can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Terbinafine.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Terbinafine.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Terbinafine.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Terbinafine.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Terbinafine.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Terbinafine.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Terbinafine.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Terbinafine.Approved
PyrimethamineThe metabolism of Terbinafine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Terbinafine.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Terbinafine.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Terbinafine.Approved
RabeprazoleThe metabolism of Terbinafine can be decreased when combined with Rabeprazole.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Terbinafine.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Terbinafine.Approved, Investigational
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Terbinafine.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Terbinafine.Investigational
RifabutinThe metabolism of Terbinafine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Terbinafine can be increased when combined with Rifampicin.Approved
RifampicinThe serum concentration of Terbinafine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Terbinafine can be increased when combined with Rifapentine.Approved
RisedronateThe risk or severity of adverse effects can be increased when Terbinafine is combined with Risedronate.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Terbinafine.Approved, Investigational
RitonavirThe metabolism of Terbinafine can be decreased when combined with Ritonavir.Approved, Investigational
RopiniroleThe metabolism of Terbinafine can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Terbinafine.Approved
RosiglitazoneThe metabolism of Terbinafine can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotineThe metabolism of Rotigotine can be decreased when combined with Terbinafine.Approved
SaquinavirThe metabolism of Terbinafine can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Terbinafine.Approved
SecobarbitalThe metabolism of Terbinafine can be increased when combined with Secobarbital.Approved, Vet Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Terbinafine.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Terbinafine.Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Terbinafine.Approved, Investigational
SiltuximabThe serum concentration of Terbinafine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Terbinafine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Terbinafine.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Terbinafine.Approved
SorafenibThe metabolism of Terbinafine can be decreased when combined with Sorafenib.Approved, Investigational
SparteineThe metabolism of Sparteine can be decreased when combined with Terbinafine.Experimental
St. John's WortThe serum concentration of Terbinafine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Terbinafine can be increased when it is combined with Stiripentol.Approved
SucralfateSucralfate can cause a decrease in the absorption of Terbinafine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulfadiazineThe metabolism of Terbinafine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Terbinafine can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Terbinafine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Terbinafine.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Terbinafine.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Terbinafine resulting in a loss in efficacy.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Terbinafine.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Terbinafine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Terbinafine.Investigational, Withdrawn
TelaprevirThe metabolism of Terbinafine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Terbinafine can be decreased when combined with Telithromycin.Approved
TenofovirThe metabolism of Terbinafine can be decreased when combined with Tenofovir.Approved, Investigational
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Terbinafine.Withdrawn
TeriflunomideThe serum concentration of Terbinafine can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Terbinafine.Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Terbinafine.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Terbinafine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Terbinafine.Approved
TianeptineThe metabolism of Tianeptine can be decreased when combined with Terbinafine.Approved
TicagrelorThe metabolism of Terbinafine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Terbinafine can be decreased when combined with Ticlopidine.Approved
TimololThe metabolism of Timolol can be decreased when combined with Terbinafine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Terbinafine.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Terbinafine.Approved, Investigational
TocilizumabThe serum concentration of Terbinafine can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Terbinafine can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Terbinafine is combined with Tolfenamic Acid.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Terbinafine.Approved, Investigational
TopiramateThe metabolism of Terbinafine can be decreased when combined with Topiramate.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Terbinafine.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Terbinafine.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Terbinafine is combined with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Terbinafine can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Terbinafine.Approved, Investigational
TrimethoprimThe metabolism of Terbinafine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Terbinafine.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Terbinafine.Approved
Valproic AcidThe metabolism of Terbinafine can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Terbinafine can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Terbinafine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Terbinafine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Terbinafine is combined with Verapamil.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Terbinafine.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Terbinafine.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Terbinafine.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Vinpocetine.Investigational
VoriconazoleThe metabolism of Terbinafine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Terbinafine.Approved
XylometazolineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Xylometazoline.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Terbinafine.Approved, Vet Approved
ZafirlukastThe metabolism of Terbinafine can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Terbinafine.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Terbinafine is combined with Ziconotide.Approved
ZiprasidoneThe metabolism of Terbinafine can be decreased when combined with Ziprasidone.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Terbinafine.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Terbinafine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Graziano Castaldi, “Process for the preparation of terbinafine.” U.S. Patent US20020123651, issued September 05, 2002.

US20020123651
General References
  1. Darkes MJ, Scott LJ, Goa KL: Terbinafine: a review of its use in onychomycosis in adults. Am J Clin Dermatol. 2003;4(1):39-65. [PubMed:12477372 ]
  2. Klobucnikova V, Kohut P, Leber R, Fuchsbichler S, Schweighofer N, Turnowsky F, Hapala I: Terbinafine resistance in a pleiotropic yeast mutant is caused by a single point mutation in the ERG1 gene. Biochem Biophys Res Commun. 2003 Sep 26;309(3):666-71. [PubMed:12963042 ]
  3. Ryder NS: Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992 Feb;126 Suppl 39:2-7. [PubMed:1543672 ]
  4. Birnbaum JE: Pharmacology of the allylamines. J Am Acad Dermatol. 1990 Oct;23(4 Pt 2):782-5. [PubMed:2229523 ]
  5. McClellan KJ, Wiseman LR, Markham A: Terbinafine. An update of its use in superficial mycoses. Drugs. 1999 Jul;58(1):179-202. [PubMed:10439936 ]
  6. Krishnan-Natesan S: Terbinafine: a pharmacological and clinical review. Expert Opin Pharmacother. 2009 Nov;10(16):2723-33. doi: 10.1517/14656560903307462. [PubMed:19874252 ]
  7. Gianni C: Update on antifungal therapy with terbinafine. G Ital Dermatol Venereol. 2010 Jun;145(3):415-24. [PubMed:20461049 ]
  8. Korting HC, Kiencke P, Nelles S, Rychlik R: Comparable efficacy and safety of various topical formulations of terbinafine in tinea pedis irrespective of the treatment regimen: results of a meta-analysis. Am J Clin Dermatol. 2007;8(6):357-64. [PubMed:18039018 ]
External Links
ATC CodesD01BA02D01AE15
AHFS Codes
  • 08:14.04
  • 84:04.08.04
PDB EntriesNot Available
FDA labelDownload (137 KB)
MSDSDownload (73.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9876
Blood Brain Barrier+0.9381
Caco-2 permeable+0.7436
P-glycoprotein substrateSubstrate0.6026
P-glycoprotein inhibitor INon-inhibitor0.7495
P-glycoprotein inhibitor IIInhibitor0.8205
Renal organic cation transporterNon-inhibitor0.581
CYP450 2C9 substrateNon-substrate0.7806
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6461
CYP450 1A2 substrateNon-inhibitor0.5
CYP450 2C9 inhibitorNon-inhibitor0.8951
CYP450 2D6 inhibitorInhibitor0.6772
CYP450 2C19 inhibitorNon-inhibitor0.6194
CYP450 3A4 inhibitorNon-inhibitor0.6314
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5884
Ames testNon AMES toxic0.8736
CarcinogenicityCarcinogens 0.5109
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8932 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8785
hERG inhibition (predictor II)Non-inhibitor0.5566
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis consumer health inc
  • Novartis pharmaceuticals corp
  • Taro pharmaceuticals usa inc
  • Apotex corp
  • Aurobindo pharma ltd
  • Breckenridge pharmaceutical inc
  • Dr reddys laboratories inc
  • Gedeon richter usa inc
  • Genpharm inc
  • Glenmark generics ltd
  • Harris pharmaceutical inc
  • Invagen pharmaceuticals inc
  • Mylan pharmaceuticals inc
  • Orchid healthcare
  • Roxane laboratories inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Wockhardt ltd
Packagers
Dosage forms
FormRouteStrength
TabletOral125 mg
GranuleOral125 mg/1
GranuleOral187.5 mg/1
SprayTopical1.25 mL/125mL
CreamTopical10 mg/g
SprayTopical1 mL/100mL
GelTopical10 mg/g
LiquidTopical1.25 mL/125mL
CreamTopical1 g/100g
CreamTopical1 %
GelTopical10 mg
SprayTopical10 mg
TabletOral250 mg
SprayTopical1 %
TabletOral250 1/1
TabletOral250 mg/1
Prices
Unit descriptionCostUnit
LamISIL 14 187.5 mg Packets Packet202.16USD packet
LamISIL 1% Solution 30ml Bottle88.18USD bottle
Terbinafine hcl powder42.84USD g
Terbinafine HCl 1% Cream 24 gm Tube17.99USD tube
Lamisil 250 mg tablet14.22USD tablet
Terbinafine hcl 250 mg tablet13.19USD tablet
Lamisil 250 mg Tablet4.79USD tablet
Apo-Terbinafine 250 mg Tablet2.64USD tablet
Co Terbinafine 250 mg Tablet2.64USD tablet
Mylan-Terbinafine 250 mg Tablet2.64USD tablet
Novo-Terbinafine 250 mg Tablet2.64USD tablet
Pms-Terbinafine 250 mg Tablet2.64USD tablet
Sandoz Terbinafine 250 mg Tablet2.64USD tablet
Lamisil 1% cream2.13USD g
Lamisil 1 % Solution0.58USD g
Lamisil 1 % Cream0.57USD g
Sm athlete's 1% foot cream0.53USD g
Lamisil at 1% cream0.51USD g
CVS Pharmacy jock itch 1% cream0.49USD g
CVS Pharmacy athlete's foot 1% cream0.4USD g
Athlete's 1% foot cream0.27USD g
Lamisil af defense crm to powd0.2USD g
Lamisil antifungal 1% spray0.07USD ml
Lamisil af defense 1% powder0.05USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2062341 No2004-05-112012-03-05Canada
CA2068957 No2002-12-172012-05-19Canada
US5681849 No1995-04-282015-04-28Us
US5856355 No1995-05-182012-05-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point195-198 °CNot Available
water solubilitySlightly solubleNot Available
logP5.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000738 mg/mLALOGPS
logP5.51ALOGPS
logP5.53ChemAxon
logS-5.6ALOGPS
pKa (Strongest Basic)8.94ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity98.08 m3·mol-1ChemAxon
Polarizability35.83 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
KingdomOrganic compounds
Super ClassBenzenoids
ClassNaphthalenes
Sub ClassNot Available
Direct ParentNaphthalenes
Alternative Parents
Substituents
  • Naphthalene
  • Benzylamine
  • Aralkylamine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Squalene monooxygenase activity
Specific Function:
Catalyzes the first oxygenation step in sterol biosynthesis and is suggested to be one of the rate-limiting enzymes in this pathway.
Gene Name:
SQLE
Uniprot ID:
Q14534
Molecular Weight:
63922.505 Da
References
  1. Sander CS, Hipler UC, Wollina U, Elsner P: Inhibitory effect of terbinafine on reactive oxygen species (ROS) generation by Candida albicans. Mycoses. 2002 Jun;45(5-6):152-5. [PubMed:12100530 ]
  2. Wentzinger LF, Bach TJ, Hartmann MA: Inhibition of squalene synthase and squalene epoxidase in tobacco cells triggers an up-regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase. Plant Physiol. 2002 Sep;130(1):334-46. [PubMed:12226513 ]
  3. Darkes MJ, Scott LJ, Goa KL: Terbinafine: a review of its use in onychomycosis in adults. Am J Clin Dermatol. 2003;4(1):39-65. [PubMed:12477372 ]
  4. Klobucnikova V, Kohut P, Leber R, Fuchsbichler S, Schweighofer N, Turnowsky F, Hapala I: Terbinafine resistance in a pleiotropic yeast mutant is caused by a single point mutation in the ERG1 gene. Biochem Biophys Res Commun. 2003 Sep 26;309(3):666-71. [PubMed:12963042 ]
  5. Leber R, Fuchsbichler S, Klobucnikova V, Schweighofer N, Pitters E, Wohlfarter K, Lederer M, Landl K, Ruckenstuhl C, Hapala I, Turnowsky F: Molecular mechanism of terbinafine resistance in Saccharomyces cerevisiae. Antimicrob Agents Chemother. 2003 Dec;47(12):3890-900. [PubMed:14638499 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Ryder NS: Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992 Feb;126 Suppl 39:2-7. [PubMed:1543672 ]
  8. Krishnan-Natesan S: Terbinafine: a pharmacological and clinical review. Expert Opin Pharmacother. 2009 Nov;10(16):2723-33. doi: 10.1517/14656560903307462. [PubMed:19874252 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Abdel-Rahman SM, Marcucci K, Boge T, Gotschall RR, Kearns GL, Leeder JS: Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos. 1999 Jul;27(7):770-5. [PubMed:10383919 ]
  2. Madani S, Barilla D, Cramer J, Wang Y, Paul C: Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. J Clin Pharmacol. 2002 Nov;42(11):1211-8. [PubMed:12412819 ]
  3. Debruyne D, Coquerel A: Pharmacokinetics of antifungal agents in onychomycoses. Clin Pharmacokinet. 2001;40(6):441-72. [PubMed:11475469 ]
  4. Abdel-Rahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL: Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Clin Pharmacol Ther. 1999 May;65(5):465-72. [PubMed:10340911 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:
Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Gene Name:
CYP11A1
Uniprot ID:
P05108
Molecular Weight:
60101.87 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:
CYP19A1
Uniprot ID:
P11511
Molecular Weight:
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:11